Mabwell (688062.SH) announced that it has received a Study May Proceed notification from the U.S. Food and Drug Administration (FDA), granting official approval for the clinical trial application of its 9MW5211 injection for the treatment of inflammatory bowel disease (IBD). Concurrently, the company's clinical trial applications for IBD and multiple other indications, including multiple sclerosis (MS), have been accepted by the National Medical Products Administration. Mabwell is also actively advancing clinical trial applications for additional indications. 9MW5211 is a highly specific, clearance-enabled innovative antibody independently developed by the company. It precisely targets the key pathological mechanisms mediated by abnormal immune cells in autoimmune diseases. The aberrant activation and tissue infiltration of immune cells are core drivers in the development and progression of various autoimmune disorders. The molecule targeted by 9MW5211 is specifically expressed on the surface of pathogenic immune cells and serves as a critical biological marker for their abnormal activation. By selectively identifying and clearing these pathogenic cells, 9MW5211 can effectively block the immune cascade, thereby alleviating disease progression and improving clinical symptoms.
Comments